Company intelligence / Profile preview
Shanghai Genomics
Shanghai, Shanghai, Chinashanghaigenomics.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
The company’s lead candidate F‑573 targets the caspase family for acute-on-chronic liver failure and has reached Phase 2. Other programs are in preclinical or pending stages targeting hepatitis B and chronic obstructive pulmonary disease. The company has a track record of successful collaborations with international partners such as Centocor and Inceptua
- Therapeutic areas
- GastroenterologyPulmonologyInfectious Diseases
- Modalities
- Small moleculeMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Centocor (now part of Johnson & Johnson)Inceptua GmbH
Beyond the preview
Go deeper on Shanghai Genomics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Genomics.